Cargando…
Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, and in silico studies
This study aimed to design anticancer theobromine derivatives inhibiting VEGFR-2. The new compounds were tested in vitro to evaluate their effectiveness against MCF-7 and HepG2 cancer cell lines. Among these compounds, 15a showed the highest cytotoxicity against HepG2, with an IC(50) value of 0.76 μ...
Autores principales: | Eissa, Ibrahim H., Yousef, Reda G., Elkady, Hazem, Elkaeed, Eslam B., Alsfouk, Aisha A., Husein, Dalal Z., Ibrahim, Ibrahim M., Elhendawy, Mostafa A., Godfrey, Murrell, Metwaly, Ahmed M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395314/ https://www.ncbi.nlm.nih.gov/pubmed/37538515 http://dx.doi.org/10.1039/d3ra04007k |
Ejemplares similares
-
A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies
por: Eissa, Ibrahim H., et al.
Publicado: (2023) -
New Anticancer Theobromine Derivative Targeting EGFR(WT) and EGFR(T790M): Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies
por: Elkaeed, Eslam B., et al.
Publicado: (2022) -
Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2
por: Eissa, Ibrahim H., et al.
Publicado: (2023) -
A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study
por: Eissa, Ibrahim H., et al.
Publicado: (2023) -
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach
por: Eissa, Ibrahim H., et al.
Publicado: (2023)